AR and neoplasm: Recently, CCS1477 was developed as a potent, selective, and orally bioavailable small-molecule inhibitor of the p300/CBP conserved bromodomain, and has been shown to inhibit cell proliferation in PCa cell lines, patient-derived xenografts, as well as in serial tumor biopsies acquired from an ongoing human phase I trial, by inhibiting AR regulated gene expression independent of c-MYC signaling (145).